{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:00:23Z","timestamp":1790258423388,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40261-026-01588-2","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:09:11Z","timestamp":1787144951000},"page":"1187-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Tolerability of Fexinidazole in Subjects with Hepatic Impairment"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2583-7704","authenticated-orcid":false,"given":"Matthieu","family":"Gassiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Beaucire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lezzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Beauchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"1588_CR1","unstructured":"Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organization. 1998;881:1\u2013114. https:\/\/www.who.int\/publications\/i\/item\/WHO-TRS-881 . Accessed 22 June 2026."},{"key":"1588_CR2","unstructured":"Neglected diseases data interactive map 2018. World Health Organization. Cited December 2024. https:\/\/apps.who.int\/neglected_diseases\/ntddata\/hat\/hat.html. Accessed 22 June 2026."},{"issue":"11","key":"1588_CR3","doi-asserted-by":"publisher","first-page":"e1665","DOI":"10.1016\/S2214-109X(22)00338-2","volume":"10","author":"VKB Kumesu","year":"2022","unstructured":"Kumesu VKB, Kalonji WM, Bardonneau C, Mordt OV, Tete DN, Blesson S, et al. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, Phase 2\u20133 trial. Lancet Glob Health. 2022;10(11):e1665\u201374.","journal-title":"Lancet Glob Health"},{"key":"1588_CR4","first-page":"257","volume":"6","author":"JR Franco","year":"2014","unstructured":"Franco JR, Simarro PP, Diarra A, Jannin JG. Epidemiology of human African trypanosomiasis. Clin Epidemiol. 2014;6:257\u201375.","journal-title":"Clin Epidemiol"},{"key":"1588_CR5","unstructured":"Sanofi. Fexinidazole tablets [package insert]. U.S. Food and Drug Administration website. Revised September 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214429s003s004lbl.pdf. Accessed 22 June 2026."},{"issue":"12","key":"1588_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000923","volume":"4","author":"E Torreele","year":"2010","unstructured":"Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, et al. Fexinidazole\u2014a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4(12):e923.","journal-title":"PLoS Negl Trop Dis"},{"key":"1588_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40262-014-0136-3","volume":"53","author":"A Tarral","year":"2014","unstructured":"Tarral A, Blesson S, Mordt OV, Torreele E, Sassella D, Bray MA, et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clin Pharmacokinet. 2014;53:565\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1588_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020128","volume":"15","author":"M Imran","year":"2022","unstructured":"Imran M, Khan SA, Alshammari MK, Alqahtani AM, Alanazi TA, Kamal M, et al. Discovery, development, inventions and patent review of fexinidazole: the first all-oral therapy for human African trypanosomiasis. Pharmaceuticals (Basel). 2022;15(2):128.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1588_CR9","unstructured":"WHO model list of essential medicines\u201421st list, 2019. World Health Organization. 2019. https:\/\/www.who.int\/publications\/i\/item\/WHOMVPEMPIAU2019.06. Accessed 22 June 2026."},{"key":"1588_CR10","unstructured":"Report of the WHO stakeholders update webinar on human African trypanosomiasis. World Health Organization; 2025:1\u201354. Report of the WHO stakeholders update webinar on human African trypanosomiasis, Geneva, Switzerland, 5 June 2025. Accessed 22 June 2026."},{"key":"1588_CR11","unstructured":"Acoziborole Winthrop 320 mg tablets. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-product-information\/acoziborole-winthrop-product-information_en.pdf. Accessed 22 June 2026."},{"key":"1588_CR12","unstructured":"Fexinidazole Winthrop 600 mg tablets. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-product-information\/fexinidazole-winthrop-product-information_en.pdf . Accessed 23 June 2026."},{"issue":"2","key":"1588_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40261-025-01508-w","volume":"46","author":"M Gassiot","year":"2026","unstructured":"Gassiot M, Brun P, Wauthier V, et al. Supplementary information for: unexpected clinical drug-drug interaction of fexinidazole on midazolam pharmacokinetics: insights into underlying mechanisms from clinical Phase I study results and supporting in vivo\/vitro evidence. Clin Drug Investig. 2026;46(2):221\u201336.","journal-title":"Clin Drug Investig"},{"key":"1588_CR14","unstructured":"Fexinidazole tablets, for oral use. Initial U.S. Approval: 2021. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214429s000lbl.pdf. Accessed 22 June 2026."},{"key":"1588_CR15","unstructured":"U.S. Food and Drug Administration. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. May 2003. Available at: FDA Guidance Documents. https:\/\/www.fda.gov\/media\/71311\/download. Accessed 22 June 2026."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01588-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:13:48Z","timestamp":1790255628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01588-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01588-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Matthieu Gassiot, Jean Pierre Beaucire and C\u00e9line Beauchard are employees of Sanofi and may hold stocks and\/or stock options in the company. Eric Sultan was an employee of Sanofi when this study was conducted and may hold stock and\/or stock options. Sophie Hays and Sarah Lezzar have no conflicts of interest directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are derived from the submitted clinical study report (CSR) and regulatory dossier (2.7.2). These data are not openly available to maintain the confidentiality and privacy of the study participants. For more information, please contact the corresponding author.","order":2,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles laid down by the Declaration of Helsinki and Good Clinical Practice guidelines (EudraCT No: 2021-004580-27). The study was approved by the Ethics Committee of the Comit\u00e9 de Protection des Personnes (CPP) Sud-Ouest et Outre-Mer II, ARS Occitanie, Toulouse, France (Protocol No. POP17145 V3.0 of 10 March, 2023) and the Ethics Committee for Clinical Trials (ECCT), Sofia, Bulgaria (Notification No. POP17145 V3.0 of 24 April, 2023).","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants before their inclusion in the study. Participants were informed of the nature of the trial, its aim, its possible risks, its duration and the compensation they would receive before their selection for the study. All the participants freely gave their written informed consent before any study-related procedures were conducted. A copy of the informed consent forms (ICFs) was given to the participant.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G.M. performed formal analyses and interpretation of results. J.P.B. conducted safety assessments. H.S. served as the principal investigator of the study. S.L. performed formal analyses. C.B. led the project. E.S. conceptualised the study and interpreted the results. G.M., J.P.B. and C.B. contributed to writing\u2014review and editing of the manuscript. All authors reviewed the manuscript critically and approved the final version. All authors agreed to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}